<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00399165</url>
  </required_header>
  <id_info>
    <org_study_id>06-2962-A</org_study_id>
    <secondary_id>U54HD042454</secondary_id>
    <secondary_id>K23HD045386</secondary_id>
    <nct_id>NCT00399165</nct_id>
  </id_info>
  <brief_title>Oral Androgens in Man-4: (Short Title: Oral T-4)</brief_title>
  <official_title>Oral Androgens in Man-4: Gonadotropin Suppression Medicated by Oral Testosterone Enanthate in Oil Plus Dutasteride (Short Title: Oral T-4)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The protocol was designed to address the hypothesis that oral testosterone enanthate plus
      dutasteride can suppress the secretion of LH and FSH after four weeks of administration. In
      addition, we will compare the gonadotropin suppression mediated by a dose of testosterone
      enanthate (400 mg twice daily) that would be expected to maintain the serum testosterone in
      the normal range throughout the day, with the same dose (800 mg once daily) administered once
      daily. This larger once-daily dose is expected to result in a higher peak and lower trough by
      the end of the dosing interval
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be carried out in a double-blinded fashion, so neither the subject nor the
      investigator will be aware of treatment assignment during the study. This protocol is
      designed to address the hypothesis that oral testosterone enanthate plus dutasteride can
      suppress the secretion of LH and FSH after four weeks of administration. In addition, we will
      compare the gonadotropin suppression mediated by a dose of testosterone enanthate (400 mg
      twice daily) that would be expected to maintain the serum testosterone in the normal range
      throughout the day, with the same dose (800 mg once daily) administered once daily. This
      larger once-daily dose is expected to result in a higher peak and lower trough by the end of
      the dosing interval. Secondary endpoints in this study include the ability of oral
      testosterone enanthate plus dutasteride to maintain short-term androgen-mediated endpoints
      such as mood and sexual function over the 4-week treatment period as well as weekly measures
      of safety, including blood counts, PSA and liver and kidney function.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dutasteride can suppress the secretion of LH and FSH after four weeks of administration.</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The ability of oral testosterone enanthate plus dutasteride to maintain short-term androgen-medicated endpoints such as mood and sexual function over the 4-week treatment period</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Testosterone enanthate in sesame oil, 400 mg po (orally), BID (twice daily) + dutasteride 0.5 mg orally, qd (once daily) for 28 days + dutasteride load 24.5 mg po once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral Testosterone sesame oil, 800 mg po (orally), qd (in am daily) + placebo sesame oil (in pm daily) + dutasteride 0.5 mg orally, qd (once daily) for 28 days + dutasteride load 24.5 mg po once</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Enanthate</intervention_name>
    <description>Oral Testosterone 400 mg orally for 28 days</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Delatestryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Enanthate</intervention_name>
    <description>Oral Testosterone 800 mg orally for 28 days</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Delatestryl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride</intervention_name>
    <description>dutasteride 0.5 mg orally, once daily for 28 days</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Avodart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo sesame oil</intervention_name>
    <description>placebo sesame oil</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dutasteride</intervention_name>
    <description>24.5 mg po once (Day 0)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Avodart</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males between 18 to 55 years of age

          -  In good general health based on normal screening evaluation (consisting of a medical
             history, physical exam, normal serum chemistry, hematology, and baseline hormone
             levels)

          -  Subject must agree not to participate in another research drug study for the duration
             of the study

          -  Subject must agree to not donate blood during the study

          -  Subject must be willing to comply with the study protocol and procedures

        Exclusion Criteria:

          -  Men in poor general health, with abnormal blood results (clinical laboratory tests or
             hormone values)

          -  A known history of alcohol or drug abuse

          -  A history of testicular disease or severe testicular trauma,

          -  A history of bleeding disorders or current use of anti-coagulants

          -  A history of sleep apnea and/or major psychiatric disorders

          -  A body-mass index greater than 35,

          -  A history of or current use of testosterone

          -  Infertility
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John K Amory, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://depts.washington.edu/popctr/</url>
    <description>University of Washington</description>
  </link>
  <reference>
    <citation>Martin CW, Anderson RA, Cheng L, Ho PC, van der Spuy Z, Smith KB, Glasier AF, Everington D, Baird DT. Potential impact of hormonal male contraception: cross-cultural implications for development of novel preparations. Hum Reprod. 2000 Mar;15(3):637-45.</citation>
    <PMID>10686211</PMID>
  </reference>
  <reference>
    <citation>Weston GC, Schlipalius ML, Bhuinneain MN, Vollenhoven BJ. Will Australian men use male hormonal contraception? A survey of a postpartum population. Med J Aust. 2002 Mar 4;176(5):208-10.</citation>
    <PMID>11999235</PMID>
  </reference>
  <reference>
    <citation>Heinemann K, Saad F, Wiesemes M, White S, Heinemann L. Attitudes toward male fertility control: results of a multinational survey on four continents. Hum Reprod. 2005 Feb;20(2):549-56. Epub 2004 Dec 17.</citation>
    <PMID>15608042</PMID>
  </reference>
  <reference>
    <citation>Amory JK, Bremner WJ. Oral testosterone in oil plus dutasteride in men: a pharmacokinetic study. J Clin Endocrinol Metab. 2005 May;90(5):2610-7. Epub 2005 Feb 15.</citation>
    <PMID>15713724</PMID>
  </reference>
  <reference>
    <citation>Amory JK, Page ST, Bremner WJ. Oral testosterone in oil: pharmacokinetic effects of 5alpha reduction by finasteride or dutasteride and food intake in men. J Androl. 2006 Jan-Feb;27(1):72-8.</citation>
    <PMID>16400081</PMID>
  </reference>
  <reference>
    <citation>Bebb RA, Anawalt BD, Christensen RB, Paulsen CA, Bremner WJ, Matsumoto AM. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach. J Clin Endocrinol Metab. 1996 Feb;81(2):757-62.</citation>
    <PMID>8636300</PMID>
  </reference>
  <reference>
    <citation>Anawalt BD, Bebb RA, Bremner WJ, Matsumoto AM. A lower dosage levonorgestrel and testosterone combination effectively suppresses spermatogenesis and circulating gonadotropin levels with fewer metabolic effects than higher dosage combinations. J Androl. 1999 May-Jun;20(3):407-14.</citation>
    <PMID>10386821</PMID>
  </reference>
  <reference>
    <citation>Anawalt BD, Amory JK, Herbst KL, Coviello AD, Page ST, Bremner WJ, Matsumoto AM. Intramuscular testosterone enanthate plus very low dosage oral levonorgestrel suppresses spermatogenesis without causing weight gain in normal young men: a randomized clinical trial. J Androl. 2005 May-Jun;26(3):405-13.</citation>
    <PMID>15867009</PMID>
  </reference>
  <results_reference>
    <citation>Amory JK, Kalhorn TF, Page ST. Pharmacokinetics and pharmacodynamics of oral testosterone enanthate plus dutasteride for 4 weeks in normal men: implications for male hormonal contraception. J Androl. 2008 May-Jun;29(3):260-71. Epub 2007 Nov 28.</citation>
    <PMID>18046048</PMID>
  </results_reference>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2006</study_first_submitted>
  <study_first_submitted_qc>November 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2006</study_first_posted>
  <last_update_submitted>September 18, 2008</last_update_submitted>
  <last_update_submitted_qc>September 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>John K Amory, MD, MPH</name_title>
    <organization>University of Washington</organization>
  </responsible_party>
  <keyword>Oral Contraception for Men</keyword>
  <keyword>Contraceptive agent</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
    <mesh_term>Dutasteride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

